ArticleBiomicrofluidics2020
A liver-on-a-chip for hepatoprotective activity assessment.
Article in Biomicrofluidics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 38 citations in OpenAlex.
- Review
- Liver-on-a-Chip (LoC) Models: Case Studies of Academic Platforms and Commercial Products.Molecular pharmaceutics · 2026Review
- Microfluidic engineering of immune-competent organs-on-chips and their applications.Frontiers in immunology · 2026Review
- Targeted cellular depletion in an immune-liver-on-a-chip platform elucidates cell-type-specific heterogeneity in drug-induced hepatotoxicity.Communications biology · 2025Article
- Advanced Strategies in Enhancing the Hepatoprotective Efficacy of Natural Products: Integrating Nanotechnology, Genomics, and Mechanistic Insights.ACS biomaterials science & engineering · 2025Review
- Assessing immune hepatotoxicity of troglitazone with a versatile liver-immune-microphysiological-system.Frontiers in pharmacology · 2024Article
- Bio-inspired microfluidics: A review.Biomicrofluidics · 2023Review
- Opportunities and considerations for studying liver disease with microphysiological systems on a chip.Lab on a chip · 2023Review
- Editorial: Organ mimicking technologies and their applications in drug discovery.Frontiers in bioengineering and biotechnology · 2023Article
- Current Research Trends in the Application of In Vitro Three-Dimensional Models of Liver Cells.Pharmaceutics · 2022Review
- Liver-on-a-chip: Considerations, advances, and beyond.Biomicrofluidics · 2022Review
- Fabrication of Concave Microwells and Their Applications in Micro-Tissue Engineering: A Review.Micromachines · 2022Review
- Implementing organ-on-chip in a next-generation risk assessment of chemicals: a review.Archives of toxicology · 2022Review
- Engineering Hydrogels for the Development of Three-Dimensional In Vitro Models.International journal of molecular sciences · 2022Review
- Rhoifolin Alleviates Alcoholic Liver DiseaseFrontiers in pharmacology · 2022Article
- Design and Fabrication of Organ-on-Chips: Promises and Challenges.Micromachines · 2021Review
- Real-time monitoring of liver fibrosis through embedded sensors in a microphysiological system.Nano convergence · 2021Article
- Critical Considerations for the Design of Multi-Organ Microphysiological Systems (MPS).Frontiers in cell and developmental biology · 2021Review
- Scaffold-mediated liver regeneration: A comprehensive exploration of current advances.Journal of tissue engineeringReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatoprotectant is critical for the treatment of liver disease. This study first reported the application of a liver chip in the hepatoprotective effect assessment. We first established a biomimetic sinusoid-on-a-chip by laminating four types of hepatic cell lines (HepG2, HUVEC, LX-2, and U937 cells) in a single microchannel with the help of laminar flow in the microchannel and some micro-fences. This chip was straightforward to fabricate and operate and was able to be long-term cultured. It also demonstrated better hepatic activity (cell viability, albumin synthesis, urea secretion, and cytochrome P450 enzyme activities) over the traditional planar cell culture model. Then, we loaded three hepatoprotectants (tiopronin, bifendatatum, and glycyrrhizinate) into the chip followed by the addition of acetaminophen as a toxin. We successfully observed the hepatoprotective effect of these hepatoprotectants in the chip, and we also found that bifendatatum predominantly reduced alanine transaminase secretion, tiopronin predominantly reduced lactate dehydrogenase secretion, and glycyrrhizinate predominantly reduced aspartate transaminase secretion, which revealed the different mechanisms of these hepatoprotectants and provided a clue for following molecular biological study of the protecting mechanism.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.